| First Author | Katewa A | Year | 2021 |
| Journal | PLoS One | Volume | 16 |
| Issue | 1 | Pages | e0244439 |
| PubMed ID | 33444326 | Mgi Jnum | J:301434 |
| Mgi Id | MGI:6505526 | Doi | 10.1371/journal.pone.0244439 |
| Citation | Katewa A, et al. (2021) The peptide symporter SLC15a4 is essential for the development of systemic lupus erythematosus in murine models. PLoS One 16(1):e0244439 |
| abstractText | Systemic Lupus Erythematosus (SLE) is a chronic autoimmune disease representing a serious unmet medical need. The disease is associated with the loss of self-tolerance and exaggerated B cell activation, resulting in autoantibody production and the formation of immune complexes that accumulate in the kidney, causing glomerulonephritis. TLR7, an important mediator of the innate immune response, drives the expression of type-1 interferon (IFN), which leads to expression of type-1 IFN induced genes and aggravates lupus pathology. Because the lysosomal peptide symporter slc15a4 is critically required for type-1 interferon production by pDC, and for certain B cell functions in response to TLR7 and TLR9 signals, we considered it as a potential target for pharmacological intervention in SLE. We deleted the slc15a4 gene in C57BL/6, NZB, and NZW mice and found that pristane-challenged slc15a4-/- mice in the C57BL/6 background and lupus prone slc15a4-/- NZB/W F1 mice were both completely protected from lupus like disease. In the NZB/W F1 model, protection persisted even when disease development was accelerated with an adenovirus encoding IFNalpha, emphasizing a broad role of slc15a4 in disease initiation. Our results establish a non-redundant function of slc15a4 in regulating both innate and adaptive components of the immune response in SLE pathobiology and suggest that it may be an attractive drug target. |
